Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders

Rhea-AI Summary

Avalon GloboCare (NASDAQ: ALBT) has announced a wholesale distribution agreement between its subsidiary Q&A Distribution and Saga Health Corporation for the KetoAir™ breathalyzer device. The device will be integrated into Saga Health's Holistic Health Reset Program targeting first responders.

KetoAir™, registered with the FDA (#3026284320), is a handheld device that measures breath acetone concentration (BrAce) to monitor ketosis and fat metabolism. The device features nano-sensor technology, provides real-time insights, and is compatible with both iOS and Android platforms through dedicated mobile apps.

Positive

• New distribution agreement expands commercial reach of KetoAir™
• FDA-registered device with established regulatory compliance
• Cross-platform compatibility (iOS and Android) increases market accessibility

Negative

• No financial terms or revenue projections disclosed
• Limited initial target market focused only on first responders

Insights

Medical Technology Analyst

Avalon's KetoAir distribution deal with Saga Health opens new revenue stream in first responder market, expanding commercial reach.

Avalon GloboCare's subsidiary has secured a strategic distribution agreement with Saga Health Corporation for its FDA-registered KetoAir™ breathalyzer device, specifically targeting the first responder market through Saga's Holistic Health Reset Program. This represents a targeted commercial expansion into a specialized healthcare segment.

The KetoAir™ device leverages nano-sensor technology to measure breath acetone concentration (BrAce), a critical biomarker for monitoring ketosis and fat metabolism. This technology has practical applications across multiple use cases: weight management, athletic performance optimization, and therapeutic ketogenic diet monitoring - making it versatile for various consumer segments.

What makes this deal particularly notable is the entry into the first responder market - a population with unique health challenges and metabolic demands due to irregular schedules, high stress, and physical requirements. First responders represent not just a new customer base but potentially a long-term recurring revenue opportunity if the product demonstrates value within Saga Health's program.

The device's dual platform compatibility (iOS and Android) enhances its market accessibility, while its FDA registration (number 3026284320) provides regulatory validation. This partnership suggests Avalon is executing a specialized distribution strategy rather than relying solely on direct-to-consumer channels, which could accelerate market penetration and provide more predictable revenue streams.

FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that its subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation (“Saga Health”) for its use of the KetoAir™ breathalyzer device in its first responder-targeted Holistic Health Reset Program.

KetoAir™ is a handheld breathalyzer designed for ketogenic health management (U.S. Food and Drug Administration registration number: 3026284320). It measures breath acetone concentration (BrAce), a key indicator of fat metabolism and ketosis. Intended for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, the device utilizes nano-sensor technology to provide real-time insights. KetoAir™ is compatible with both Apple and Android devices and is available via the Apple App Store and Google Play Store.

“We believe that this agreement with Saga Health marks a milestone in accelerating the commercial expansion of KetoAir™,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “KetoAir™ is a unique, science-driven tool that supports the growing demand for personalized, real-time monitoring of BrAce, and is intended for those pursuing ketogenic lifestyles. We’re pleased to collaborate with our partner Saga Health to further our goal of accelerating the commercial expansion of the KetoAir™.”

“We are very happy to partner with Avalon GloboCare to introduce the KetoAir™ to the first responders in our Holistic Health Reset Program,” said Thomas Tauzin, CEO of Saga Health.

To learn more or purchase your own KetoAir™ device, visit www.ketoair.us.

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device, which is owned and manufactured by Qi Diagnostics Limited, and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir™ is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate. For more information about Avalon, please visit www.avalon-globocare.com.

About Saga Health Corp.
Saga Health Corporation offers a comprehensive wellness journey called the Holistic Health Reset Program, created to help participants take control of their health. The program provides personalized nutritional guidance, coaching, and tools like the KetoAir™ breathalyzer with the goal to improve metabolic, physical, and behavioral health. Saga Health’s programs are tailored for groups such as first responders, using themed daily content to drive engagement and accountability.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).

Additional Information About the Proposed Merger for Investors and Shareholders

This communication relates to the proposed merger (the “proposed Merger”) of Avalon and YOOV Group Holding Limited (“YOOV”). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4, as amended, that contains a preliminary prospectus and preliminary proxy statement of Avalon (the “proxy statement/prospectus”). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon’s stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.

Participants in the Solicitation

Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon’s directors and executive officers is available in Avalon’s Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com

FAQ

What is the new distribution agreement between Avalon GloboCare (ALBT) and Saga Health?

Avalon's subsidiary Q&A Distribution has entered a wholesale distribution agreement with Saga Health to provide KetoAir™ breathalyzer devices for their first responder-targeted Holistic Health Reset Program.

What is KetoAir™ and how does it work?

KetoAir™ is an FDA-registered handheld breathalyzer that measures breath acetone concentration (BrAce) using nano-sensor technology to monitor ketosis and fat metabolism in real-time.

Is KetoAir™ compatible with both iPhone and Android devices?

Yes, KetoAir™ is compatible with both Apple and Android devices, with apps available on the Apple App Store and Google Play Store.

What is the FDA registration number for Avalon's KetoAir™ device?

The KetoAir™ breathalyzer device has an FDA registration number of 3026284320.

Who is the target market for KetoAir™?

KetoAir™ is designed for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, with initial distribution focusing on first responders through Saga Health's program.